Researchers at the Federal University of Rio de Janeiro (UFRJ) and the State University of Rio de Janeiro (UERJ) have made a discovery that may lead to the development of a treatment capable of acting against more than half the cases of breast cancer.
Using resveratrol, a bioactive compound found in grapes and red wine, scientists were able for the first time to inhibit the agglomeration of mutant versions of the p53 protein, a structure present in about 60% of tumours, and to prevent migration and proliferation of breast cancer cells.
The potential anti-cancer effects of resveratrol have been known for years, but to date no study has been able to show that the substance can act to reduce tumours caused by the aggregation of the mutant form of tumour suppressor p53.
The Brazilians are the first to obtain this result in the laboratory.
Because they are found in more than half of malignant tumours, amyloid aggregates of mutant p53 are considered novel strategic targets in the fight against cancer.
In its normal, unmutated version, the protein is responsible for the suppression of tumour cells, and for this reason is often referred to as “guardian of the genome”.
A mutant p53, however, can lose that function and gain others, sequestering its normal counterparts and contributing to the formation of amyloid aggregates, structures of difficult degradation and rapid growth.
Some p53 mutations are extremely pathogenic, while others are harmless.
The laboratory of Jerson Lima Silva, professor of the Institute of Medical Biochemistry Leopoldo de Meis (IBqM) and the National Center for Structural Biology and Bioimaging (CENABIO) of UFRJ and coordinator of the National Institute of Science and Technology of the same name (INBEB), has been investigating the amyloid aggregation of p53 for two decades.
The main goal of this group is to understand the mechanisms that allow aggregates of mutant p53 to contribute to cancer and to find an effective way to prevent it from forming.
“The findings bring scientists closer to the development of a drug capable of acting directly on the amyloid aggregation of the mutant p53”, states Danielly C. Ferraz da Costa, a co-author of the study, from the Institute of Nutrition of UERJ and a member of the INBEB.
She began studying the properties of resveratrol for her doctoral thesis, and by 2012 had already investigated the anticancer protection by resveratrol in lung tumour cells.
The researchers applied fluorescence spectroscopy techniques in vitro to test the antitumour potential of resveratrol in aggregations of wild and mutant p53.
In addition, they used immunofluorescence co-localisation assays to test the action of the substance on breast cancer cells with different p53 mutants (MDA-MB-231 and HCC-70) and normal p53 (MCF-7). Decreased aggregation of mutated p53 was observed in tumours implanted in mice.
The group is now studying various molecules derived from resveratrol that can be used in therapy against tumours containing mutated p53.